logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Aikou Okamoto

the jikei university school of medicine
H指数:51
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic value of KELIM in Japanese patients with advanced high-grade serous ovarian carcinoma and its association with pathological absence of malignancy at interval debulking surgery: A retrospective study

KELIM在日本晚期高级别浆液性卵巢癌患者中的预后价值及其与间隔减瘤术后病理无恶性残留的相关性：一项回顾性研究

Therapeutic Advances in Medical Oncology
IF4.2
2026-10-190
PRE
Yuki Kochi; Daito Noguchi; Chie Nagata; Midori Ogasawara; Risako Nonaka; Ryuko Sugita; Satoshi Hosoya; Motoaki Saito; Hiroshi Tanabe; Hirokuni Takano; Kyosuke Yamada; Aikou Okamoto; Nozomu Yanaihara
Survival impact of pelvic radiotherapy plus chemotherapy in newly diagnosed stage IVB cervical cancer in Japan (JROSG22-1/JGOG1088S)

日本新诊断IVB期宫颈癌患者接受盆腔放疗联合化疗的生存影响（JROSG22-1/JGOG1088S）

Radiotherapy and Oncology
IF5.3
2026-09-010
PRE
Tsuchida, Keisuke; Ogawa, Kazunari; Toita, Takafumi; Ikushima, Hitoshi; Mizushima, Taichi; Nishio, Shin; Murotani, Kenta; Okuya, Rie; Uno, Takashi; Eto, Chika; Nishimura, Tetsuo; Saji, Haruya; Ishidera, Yumi; Tonoiso, Chisato; Takekuma, Munetaka; Okamoto, Aikou; Ohno, Tatsuya
Molecular and pathological analysis of FOXL2 and TERT promoter mutations in adult-type granulosa cell tumors of the ovary: a study of 64 Japanese patients

FOXL2和TERT启动子突变在卵巢成人型颗粒细胞瘤中的分子与病理学分析：一项对64例日本患者的病例研究

Journal of Gynecologic Oncology
IF3.7
2026-05-010
OA
Yanagida, Satoshi; Shoburu, Yuichi; Kiyokawa, Takako; Iwamoto, Masami; Saito, Misato; Suzuki, Eitaro; Noguchi, Daito; Kawabata, Ayako; Kaya, Ryusuke; Seki, Toshiyuki; Nagata, Chie; Saito, Motoaki; Takano, Hirokuni; Yamada, Kyosuke; Takenaka, Masataka; Yanaihara, Nozomu; Okamoto, Aikou
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial

Tisotumab vedotin在日本复发性或转移性宫颈癌患者中的应用：来自innovaTV 301/ENGOT-cx12/GOG-3057试验的结果

International Journal of Gynecological Cancer
IF4.7
2025-12-310
PRE
Kan Yonemori; Shin Nishio; Shiro Suzuki; Kosei Hasegawa; Mayu Yunokawa; Satoshi Yamaguchi; Aikou Okamoto; Kazuto Nakamura; Shoji Kamiura; Keiichi Fujiwara; Noriyuki Katsumata; Hiroaki Kobayashi; Tomoka Usami; Ayako Mochizuki; Kazuhiro Takehara; Elizabeth Whalley; Hidehisa Noguchi; Ibrahima Soumaoro; Brian Slomovitz; Ignace Vergote
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

Durvalumab联合卡铂/紫杉醇和贝伐单抗，然后durvalumab和贝伐单抗联合或不联合奥拉帕尼维持治疗新诊断的非BRCA突变晚期卵巢癌

Annals of Oncology
IF65.4
2025-12-090
PRE
P. Harter; F. Trillsch; A. Okamoto; A. Reuss; J.-W. Kim; M.J. Rubio-Pérez; M.A. Vardar; G. Scambia; O. Trédan; G.-B. Nyvang; N. Colombo; M. Bidziński; C. Grimm; S. Lheureux; E. Van Nieuwenhuysen; F. Heitz; R.M. Wenham; S. Nishio; M.C. Lim; G. Marquina
Perinatal outcomes in RhD-negative pregnant women in Japan
SCIENTIFIC REPORTS
IF3.9
2025-03-220
OAAI
Takahashi, Ken; Yoshida, Susumu; Aoki, Showa; Tanaka, Saori; Kawashima, Akihiro; Kajiwara, Kazuhiro; Kato, Noriko; Matsui, Hitoshi; Serizawa, Mariko; Tsuji, Shunichiro; Yamamoto, Tomoko; Kinjo, Tadatsugu; Nakamura, Noriyuki; Sagawa, Maiko; Sato, Mika; Abe, Emiko; Nakanishi, Sayuri; Fujimoto, Yoshinobu; Takahashi, Sota; Sasaki, Hiroyuki; Mukai, Yurika; Hara, Sumiko; Fukuta, Kaori; Kikuchi, Norihiko; Hara, Emiko; Shiga, Tomomi; Horiuchi, Chinami; Sado, Toshiyuki; Matsubara, Yuko; Akabane, Keiichiroh; Harada, Aya; Nagase, Hiromi; Maeda, Kazuhisa; Katagiri, Hiroshi; Sasahara, Jun; Sugii, Hirokazu; Tamaru, Shunsuke; Waratani, Miyoko; Tsukahara, Saya; Shibukawa, Shohei; Kiyama, Tomoiki; Kasuga, Yoshifumi; Egawa, Makiko; Sato, Hiroshi; Tamamura, Chiyo; Suemitsu, Tokumasa; Okamoto, Aikou; Samura, Osamu
Safety and tolerability of durvalumab (D) plus carboplatin/paclitaxel (CP) plus bevacizumab (B) followed by D, B plus olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

在DUO-O III期试验中，评估 durvalumab (D) 联合 carboplatin/paclitaxel (CP) 及 bevacizumab (B) 诱导治疗后，再给予 D、B 联合 olaparib (O) 维持治疗（mtx）在无肿瘤 BRCA1/BRCA2 突变（non-tBRCAm）的新诊断晚期卵巢癌（AOC）患者中的安全性与耐受性。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J-W.; Ospina, G. Marquina; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; Tognon, G.; Chudecka-Glaz, A. M.; Berger, R.; Lheureux, S.; Henry, S.; Burges, A.; Wenham, R. M.; Nishio, S.; Marshall, L.; Harter, P.

研究方向

暂未获取到该数据
H
Haruhiko Sago
H 指数:43论文数:481被引数:9,014
N
Nozomu Yanaihara
H 指数:29论文数:172被引数:7,680
T
Takayuki Enomoto
H 指数:63论文数:626被引数:1.7万
O
Osamu Samura
H 指数:27论文数:146被引数:2,200
D
Daisuke Aoki
H 指数:60论文数:745被引数:1.6万
K
Kazuhiro Takehara
H 指数:32论文数:245被引数:5,802
M
Masaki Mandai
H 指数:56论文数:690被引数:1.8万
A
Akihiro Umezawa
H 指数:70论文数:572被引数:1.9万
K
Kazunori Ochiai
H 指数:34论文数:200被引数:4,794
S
Satoshi Yanagida
H 指数:14论文数:46被引数:756